Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Change in Acquisitions & Divestments: 2024

Historic Change in Acquisitions & Divestments for SAB Biotherapeutics (SABS) over the last 1 years, with Dec 2024 value amounting to $25.8 million.

  • SAB Biotherapeutics' Change in Acquisitions & Divestments was N/A to $5.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $24.4 million, marking a year-over-year change of. This contributed to the annual value of $25.8 million for FY2024, which is N/A change from last year.
  • As of FY2024, SAB Biotherapeutics' Change in Acquisitions & Divestments stood at $25.8 million.
  • In the past 5 years, SAB Biotherapeutics' Change in Acquisitions & Divestments ranged from a high of $25.8 million in FY2024 and a low of $25.8 million during FY2024.
  • Over the past 1 years, SAB Biotherapeutics' median Change in Acquisitions & Divestments value was $25.8 million (recorded in 2024), while the average stood at $25.8 million.